Hosted on MSN41m
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)
Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...
Coinbase Q4 Earnings Preview: Trump Winning 2024 Election 'A Shot In The Arm For The Crypto Industry'
Cryptocurrency company Coinbase Global (NASDAQ:COIN) could highlight record profitability and user metrics when the company ...
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...
Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...
HC Wainwright Issues Pessimistic Forecast for XFOR Earnings
Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook
H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...